Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last21 to 40 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Risk of Falls in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 186,288 of 485,646 170,465 of 332,236 | -12.9 points -13.2 to -12.7 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Cases vs Controls: Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person | 797 of 150,975 2,942 of 603,770 | 0.0 points 0.0 to 0.1 | 754,745 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Cases vs Controls: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. | 2,576 of 150,975 7,563 of 603,770 | 0.5 points 0.4 to 0.5 | 754,745 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Cases vs Controls: Number of Participants With Diagnosis of Deep-vein Thrombosis After the Start of Follow-up for Each Person | 1,887 of 150,975 4,934 of 603,770 | 0.4 points 0.4 to 0.5 | 754,745 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Influenza-Like Illness (ILI) | 1,826 of 279,400 2,871 of 395,852 | -0.1 points -0.1 to -0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests | 559 of 279,400 925 of 395,852 | -0.0 points -0.1 to -0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests | 37 of 279,400 64 of 395,852 | -0.0 points -0.0 to 0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With Community-acquired Pneumonia | 106 of 279,400 183 of 395,852 | -0.0 points -0.0 to 0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With PCR-confirmed Influenza | 95 of 279,400 153 of 395,852 | -0.0 points -0.0 to 0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With All-Cause-Hospitalizations | 4,308 of 279,400 6,005 of 395,852 | 0.0 points -0.0 to 0.1 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With All-Cause Mortality | 286 of 279,400 422 of 395,852 | -0.0 points -0.0 to 0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old Hospitalized With Cardio-respiratory Events | 631 of 279,400 890 of 395,852 | 0.0 points -0.0 to 0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests | 522 of 279,400 862 of 395,852 | -0.0 points -0.1 to -0.0 | 675,252 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Cases vs Controls: Number of Female Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person | 1,506 of 89,093 4,393 of 356,311 | 0.5 points 0.4 to 0.6 | 445,404 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Cases vs Controls: Number of Participants Aged 18-44 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person | 503 of 84,253 1,592 of 337,007 | 0.1 points 0.1 to 0.2 | 421,260 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up | 167 of 85,584 747 of 320,959 | -0.0 points -0.1 to -0.0 | 406,543 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
| PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 VE for First Event of Pneumococcal Pneumonia (PP): Overall Follow-up | 309 of 85,487 1,362 of 320,959 | -0.1 points -0.1 to -0.0 | 406,446 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
| PCV13-vaccinated Participants vs Unvaccinated Participants: PCV13 VE for First Event of All-cause Pneumonia (ACP): Overall Follow-up | 8,098 of 80,591 34,498 of 320,959 | -0.7 points -0.9 to -0.5 | 401,550 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
| PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of IPD at 0-3 Years of Follow-up | 73 of 75,382 566 of 320,959 | -0.1 points -0.1 to -0.1 | 396,341 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
| PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of PP at 0-3 Years of Follow-up | 161 of 75,322 1,092 of 320,959 | -0.1 points -0.2 to -0.1 | 396,281 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=2
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05838664-fd3e43f4",
"title": "Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Risk of Falls in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC",
"summary": "186288 of 485646 against 170465 of 332236; risk difference -12.9 points, 95% interval -13.2 to -12.7; NCT05838664, A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France",
"record": "/library/comparisons/NCT05838664-fd3e43f4",
"nct_id": "NCT05838664",
"kind": "outcome",
"participants": 817882,
"risk_difference": {
"value": -0.1294960271540792,
"lower": -0.13167681979414997,
"upper": -0.12731384426530135
},
"group_1": "186,288 of 485,646",
"group_2": "170,465 of 332,236",
"difference": "-12.9 points",
"interval": "-13.2 to -12.7",
"trial_title": "A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France"
},
{
"id": "NCT04969653-94fcfe1e",
"title": "Cases vs Controls: Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person",
"summary": "797 of 150975 against 2942 of 603770; risk difference 0.0 points, 95% interval 0.0 to 0.1; NCT04969653, The Incidence of Venous Thromboembolism in Atopic Dermatitis",
"record": "/library/comparisons/NCT04969653-94fcfe1e",
"nct_id": "NCT04969653",
"kind": "outcome",
"participants": 754745,
"risk_difference": {
"value": 0.00040630327349540016,
"lower": 0.00001045503636930078,
"upper": 0.0008221125366069937
},
"group_1": "797 of 150,975",
"group_2": "2,942 of 603,770",
"difference": "0.0 points",
"interval": "0.0 to 0.1",
"trial_title": "The Incidence of Venous Thromboembolism in Atopic Dermatitis"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=3",
"request_id": "XXTsAvq-NBAT6JP8"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant